JP Morgan Chase
ENZN

JP Morgan Chase’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

JP Morgan Chase’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-340
Closed – – 5185
2016
Q1 		$0 Hold
340
– – ﹤0.01% 5188
2015
Q4 		$0 Buy
+340
New +$270 ﹤0.01% 4923
2014
Q1 		– Sell
-15,240
Closed -$18K – 4129
2013
Q4 		$18K Sell
15,240
-38,799
-72% -$59.8K ﹤0.01% 4019
2013
Q3 		$91K Buy
54,039
+36,862
+215% +$68.2K ﹤0.01% 4196
2013
Q2 		$35K Buy
+17,177
New +$50.3K ﹤0.01% 4303

Other funds holding ENZN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
MCM
Monarch Capital Management Fort Wayne, Indiana $409M AUM 17.6% 1-Year Est. Return
CFA
CT Financial Advisors Chadds Ford, Pennsylvania $162M AUM 9.58% 1-Year Est. Return

JP Morgan Chase's ENZN Position: Q2 2016 in Review

JP Morgan Chase sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2016, closing a stake of 340 shares.

JP Morgan Chase first reported a position in ENZN in Q2 2013 and held it in 5 quarters. The position peaked at $91K in Q3 2013. 10 funds tracked by Wall St. Rank hold ENZN as of Q2 2016.

  • JP Morgan Chase reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2016 after selling out during the quarter.
  • JP Morgan Chase sold 340 ENZON PHARMACEUTICALS INC shares in Q2 2016.
  • JP Morgan Chase first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 5 quarters.
  • JP Morgan Chase's ENZON PHARMACEUTICALS INC position peaked at $91K in Q3 2013.
  • 10 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2016.

Based on JP Morgan Chase's 13F filing for Q2 2016, filed 8 Aug 2016.